Key result
A newly developed LC-MS/MS method successfully quantified rivaroxaban levels in treated patients, demonstrating a significant increase from a mean pre-dose level of 123.3 ng/mL to 533.9 ng/mL at 3 hours post-dose.
Observational (n=29)
No
Absolute Event Rate: 533.93% vs 123.33%
p-value: p=<0.05
A rapid, simple, and sensitive LC-MS/MS method was successfully developed and validated for the therapeutic drug monitoring of rivaroxaban in human plasma.
Enables rivaroxaban TDM in plasma; leaves open clinical utility pending outcome studies.
A rapid, sensitive, high-throughput liquid chromatography coupled with tandem mass spectrometry method for the quantification of rivaroxaban from human plasma has been developed and validated. For the analytical separation a Zorbax SB-C18 column with isocratic flow of mobile phase composed of 0.2% formic acid in water and acetonitril (65:35, V/V) with a flow rate of 1 mL/min at a temperature of 45ºC was used. Detection of rivaroxaban was performed using positive electrospray ionization and MS/MS mode (sum of m/z 231.1; 289.2 and 318.2 from m/z 436.3). Plasma samples were prepared using single-step protein precipitation with methanol. Method validation was performed with regards to selectivity, linearity (r >0.9927), within-run and between-run precision (CV< 13.1 %) and accuracy (bias< 9.4 %) over a concentration range of 24.00 - 960.00 ng/mL plasma. Recovery was between 96.5 - 108.5% and the lower limit of quantification of rivaroxaban was 24.00 ng/mL. The developed method is simple, rapid, and selective, requires small plasma sample volumes, and was successfully applied for therapeutic drug monitoring of rivaroxaban in treated patients.
No takes yet. Share an insight, caveat, or question.
Varga et al. (2017) conducted an observational in Patients receiving rivaroxaban therapy (n=29). Rivaroxaban vs. Pre-dose baseline was evaluated on Mean rivaroxaban plasma concentration (ng/mL) (p=<0.05). A newly developed LC-MS/MS method successfully quantified rivaroxaban levels in treated patients, demonstrating a significant increase from a mean pre-dose level of 123.3 ng/mL to 533.9 ng/mL at 3 hours post-dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: